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Summary: Thyroglobulin levels were measured, without Interruption of hormone treatment, in 115 patients
who had undergone thyroidectomy for differentiated carcinoma.
Thyroglobulin levels were invariably high in patients with iodine fixing metastases. The estimation of thyro-
globulin was found to be more sensitive than the detection of metastases by their uptake of 131 iodine. A new
protocol is suggested for monitoring treated differentiated carcinoma.
Der Wert der Bestimmung der Thyroglobulinkonzentration für die Überwachung des behandelten differen-
zierten Schilddrüsencarcinoms
Zusammenfassung: Bei 115 Patienten, wegen eines differenzierten Carcinoms thyroidektomiert, wurde die
Thyroglobulinkonzentration bestimmt, ohne daß die Hormonsubstitution unterbrochen wurde.
Die Thyroglobulinkpnzentrationen waren bei Patienten mit lod-fixierenden Metastasen unverändert hoch.
Die Bestimmung von Thyroglobulin erwies sich als empfindlicher als der Nachweis von Metastasen auf Grund
ihrer 131I-Aufnahme. Ein neues Vorgehen für die Überwachung behandelter differenzierter Carcinome wird
vorgeschlagen.
Introduction
After total thyroidectomy and destruction of any re·*
sidüal cervical thyroid tissue by 131-iodine, the
monitoring of treated thyroid carcinoma was based
essentially upon the detection of ectopic areas with
uptake of 131-iodine. This investigation required the
Interruption of Substitution hormone therapy for a
sufficiently long period (3 weeks) to eiiable the me-
tastasis to take up the iodine. This method is not
without problems. The repeated administration of
131-iodine results in significant Irradiation. In par-
ticular, the hypothyroidism resulting from the inter-
ruption of treatment is a source of considerable diffi^
culties in the family and Professional life of the pa-
tients, and the increase in thyrotropin (thyroid stim-
ulating hormone, TSH) levels related to the inter-
ruption of treatment could favour the increase in
proliferation of recurrences or of the metastases.
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Can the estimation of thyroglobulin levels without
the interruptipn of Substitution hormone therapy re-
place the isotope studies using 131-iodine? The
present study was aimed at providing an answer to
this question.
Materials and Methods
Estimation of thyroglobulin
This estimation was made using a radioimmunological technique
with the Tg RIA "Henning" kit distributed in France by Hoechst
Behring. An accuracy profile (fig. 1) was undertaken using the
method of Ekins on 10 Standard curves. The maximum relative
error was 19.2% for the point 6.25 £/ , and lies between 2.6 and
4.8% for the other points of the curve; this results in an absolute
error between 1.2 ug/1 for the lowest Standard (6.25 g/l) and 14
Hg/l for the highest Standard point (400 ). In the zone where
the error should be minimal, i.e. between 6.25 g/l and 100 §/1
it is quite acceptable since it lies between 1.2 and 1.3 ng/1. Study
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of intra-assay reproducibility showed a Variation coefficient be-
tween l and 2.3%. Inter assay reproducibility, determined for 27
sera from patients measured twice in two different batches,
proved to be satisfactory. The t test applied to the mean of the
differences between these 2 paired series does not show signifi-
cant differences (t = 0.27). Tests of parallelism confirmed a good
correlation between the theoretical values and the observed re-
sults. The correlation coefficient is 0.97 with a regression line y =
0.91 χ + 0.88. The recovery test was satisfactory with recovery
rates between 81 and 92%.
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Fig. 1. Precision profile of thyroglobulin estimation.
Results
Among the 115 patients (tab. 1), 89 had a thyro-
globulin level lower, and 26 a level higher than 6.25
Tab. 1. Results of thyroglobulin assay.
Total 115
Thyro- Thyro-
globulin globulin
<6.25μg/l
Noresidues, 85 81 4
no metastasis
Residuealone 7 4 3
Non fixing metastasis 14 4 10
alone
Fixing metastasis alone 6 0 6
Residues+ 1 0 1
non fixing metastasis
Residues-f 2 0 2
fixing metastasis
89 26
Patients
The study was undertaken with 115 patients all of them with total
thyroidectomy and attending the nuclear medicine department for
a spell of 2 months.
Only patients with anti-thyroglobulin antibodies were rejected.
These antibodies were detected with a commercial kit of the
"Commissariat TEnergie Atomique" (CEA). Six patients were
seen for the first complementary treatment with 131-iodine. All
the other patients had already received 131-iodine. The survey
period lies between l month and 13 years. There were 86 females
and 29 males with a mean age of 48.3 years and extremes of 13
and 81 years. These 115 patients were divided into 23 with papil-
lary carcinomas, 33 with well differentiated follicular carcinomas
and 59 with moderately differentiated follicular carcinomas. All
measurements of thyroglobulin were made during continuing hor-
mone therapy. This consisted of triiodothyronine for 101 patients,
thyroxine for one and triiodothyronine plus thyroxine for the 13
remaining patients. The posology was adapted so that the thyro-
tropin level was low and did not rise after an injection of 250 μg of
thyroliberin (thyrotropin releasing hormone, TRH).
Whole body 131-iodine scanning
For all the patients the whole body 131-iodine scanning was per-
formed with 37 MBq (l mCi) of 131-iodine and after a sufficient-
ly long period of withdrawal of thyroid hormone so that the thyro-
tropin levels were greater than 80 mU/1. The search for ectopic
fixation of 131-iodine was made with whole body scanning 4 days
after ingestion of 37 MBq (l mCi) of 131-iodine. The measure-
ment was made with a collimated probe so that a whole transverse
slice could be studied with the same sensitivity. The sensitivity of
the system is almost 185 kBq (5 μΟί) of 131-iodine i.e. 0.5% of
the mgested dose. When a deviation is detected a scintigraphy is
performed in that region with a 400 T General Electric Gamma-
Camera.
The 89 patients with low thyroglobulin levels were
divided into 81 with neither residues nor metastases,
4 with residues only and 4 with non-fixing metas-
tases only. In this group none of the patients with
low thyroglobulin levels had any ectopic uptake of
131-iodine. Among the 4 patients with non fixing
metastases, 3 were studied before and after withdra-
wal of hormonal treatment. The thyroglobulin levels
were always lower than 6.25 μg/l.
Among the 26 patients with thyroglobulin levels
higher than 6.25 μg/l, 4 had neither residues nor me-
tastases in spite of a complete check up with clinical
and laryngologic examinations, whole body 131-io-
dine scanning, whole body bone scintigraphy with
methylene diphosphonate of 99m-techneti m, ehest
radiography and thoraco-abdominal computed to-
mography. The thyroglobulin levels were relatively
low (two with 9 μg/l and two with 13 μg/l) probably
corresponding to occult metastases. 10 patients had
non fixing metastases. In 5 of these patients, the me-
tastases were detected before the thyroglobulin as-
say or at the time of it. The thyroglobulin levels were
17, 80, 105, 150, 160 μg/l. In 3 patients, the meta-
stases were in the lungs, in one patient in the bones,
and in the bones and the mediastinum of the other
patient. In the 5 other patients the thyroglobulin lev-
els were 70, 75, 80, 125, 155 μg/l. The metastases
were detected from 3 months to 18 months after the
first iiicrease in the thyroglobulin tevel. The metasta-
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ses occurred twice in the lungs, twice in the bones
and once in the mediastinum. In the 6 patients with
fixing metastases, thyroglobulin levels were between
68 g/I and 250 g/l. In two of these patients, with
levels respectively of 130 g/l and 155 g/l, treat-
ment with 131-iodine resulted in isotopic Sterilisa-
tion and at the same time there was normalisation of
thyroglobulin levels. Six patients had residues. In 3
patients, the residues were isolated. In the other 3,
there was an association of fixing (2 cases) and non-
fixing (l case) metastases.
Among the 23 patients with metastases, only 8 had
uptake of 131-iodine showing a low sensitivity:
35%. On the other hand äs the existence of ectopic
fixation of 131-iodine may be considered to be pa-
thognomonic, the specificity of the whole body 131-
iodine scanning is 100%.
For the thyroglobulin assay, our results show a sensi-
tivity of 83% and a specificity of 95% (tab. 2).
Tab. 2. Sensitivity and specificity of whole body 131-iodine scan-
ning and thyroglobulin radioimmunoassay.
Whole body scinti- Thyroglobulin
graphic detection radioimmunoassay
with 131-iodine
Sensitivity
Specificity
35%
100%
83%
95%
Discussion
The existence of functional thyroid residues after to-
tal thyroidectomy could not be determined by the
estimation of the thyroglobulin level, since 4 of the
patients out of the 7 studied with residues had thyro-
globulin levels below 6.25 g/l. However a very high
thyroglobulin level in patients with residues could be
indicative of a suspidon of metastasis.
According to some authors (l, 2), the deteetion of
metastasis both by isotopic methods äs well äs by the
estimation of thyroglobulin level can only be carried
out validly after complete destruction of cervical re-
sidues.
Many authors have established the interest of thyro-
globulin assay for the surveillance of thyroid carcino-
mas (1-^11). Some of them think that the assay must
be combined with the whole body 131-iodine scan-
ning (12—15). For others the assay after withdrawal
of the hormonal treatnient can replace the whole
body 131-iodine scanning (l, 8-10, 16-20). Those
authors feel that we cannot estimate the thyroglobu-
lin level during hormonal treatment because of the
proved increase in thyroglobulin level äs well äs thy-
rotropin level (12, 13, 17, 21). They consider that
the sensitivity of the method decreases when the
hormonal treatment is not stopped.
On the other hand for some authors the real interest
of thyroglobulin is that it can be studied without the
withdrawal of hormonal treatment. Although it is
well known that the thyroglobulin level increases äs
well äs the thyrotropin levels, it seems that withdra-
wal of hormonal treatment does not increase the
sensitivity of thyroglobulin measurement (2, 4—7,
22). Black et al. (4) even found that the thyroglobu-
lin assay best reflects the state of the patients when
the hormonal treatment is continued.
These differences from one author to another are
perhaps due to the different normal levels used by
these authors. One author (3) even proposed differ-
ent normal ranges, depending whether the patient is
under hormonal treatment or not. If one can consid-%
er that the existence of thyroglobulin in the serum is
pathologic (more than 6,25 g/l for our method) for
patients without any residual tissue, then we feel that
the assay can be carried out under hormonal treat-
ment. This is borne out by our results.
All patients with anti-thyroglobulin antibodies were
eliminated before the study. This limitation in the
method would involve some 10% of cases of differ-
entiated thyroid carcinoma.
On the basis of these features, it would seem that a
method can be proposed for the monitoring of treat-
ed differentiated carcinoma of the thyroid. Total de-
struction of thyroid tissues by 131-iodine is made af-
ter thyroidectomy. The absence of uptake of 131-io-
dine is confirmed after three months. In the absence
of residues, thyroglobulin estimation replaces the
detection of iodine fixing metastases. The latter is
performed only if the thyroglobulin level is above
6.25 §/1. In this way, i t is possible to avoid the de-
tection of iodine fixing metastases after the interrup-
tion of hormone therapy in approximately 80% of
cases (in fact thyroglobulin levels were below 6.25
g/l in 85 patients out of 105 in our study).
Conclusion
The estimation of thyroglobulin level äs a method
for the detection of metastasis of treated differen-
tiated thyroid carcinomas is more sensitive than
whole body 131-iodine scanning. The latter tech-
nique presents some disadvantages and should be
performed only when the thyroglobulin level is high,
which reduces its indications by 80%.
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